SCHEMBL16179749

SCHEMBL16179749

COc1ccc(-c2nc(O)c3c(n2)C[S+]([O-])C3)cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 8/20 0.41
▸ PDGFRB P09619 1/20 0.41
▸ PDGFRA P16234 1/20 0.41
▸ RAB9A P51151 3/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ PDE4D Q08499 7/20 0.38
▸ ERN1 O75460 1/20 0.38
▸ MGLL Q99685 1/20 0.37
▸ CYP17A1 P05093 1/20 0.36
▸ PTGS2 P35354 3/20 0.36
▸ LMNA P02545 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ PTGS1 P23219 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18868938 0.77 PDE4B (0.49) PDE4BALDH1A1SMN1; SMN2PDE4DKDM4E
SCHEMBL16446805 0.72 PDE4B (0.44) PDE4BPDGFRBPDGFRARAB9ANPC1
SCHEMBL5733001 0.69 HSD17B10 (0.49) PDE4BALDH1A1SMN1; SMN2PDE4DLMNA
SCHEMBL6075610 0.69 MAPK1 (0.52) PDE4BALDH1A1SMN1; SMN2PDE4DLMNA
SCHEMBL17476915 0.69 PDE4B (0.41) PDE4BPDGFRBPDGFRARAB9APDE4D
SCHEMBL17476917 0.69 PDE4B (0.40) PDE4BPDGFRBPDGFRARAB9APDE4D
SCHEMBL15921292 0.68 ALDH1A1 (0.43) PDE4BPDGFRBPDGFRARAB9ANPC1
SCHEMBL16179851 0.68 PDE4B (0.43) PDE4BPDGFRBPDGFRARAB9ANPC1
SCHEMBL17476944 0.68 HSD17B10 (0.48) PDE4BPDGFRBPDGFRARAB9ANPC1
SCHEMBL5031343 0.68 RAB9A (0.57) PDGFRBPDGFRARAB9ANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2986600-B1 SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS GRUENENTHAL GMBH (DE) 2017-07-05 — — EP disclosed
US-9527832-B2 Substituted condensed pyrimidine compounds Grünenthal GmbH (DE) 2016-12-27 — — US disclosed
EP-2986600-A1 SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2016-02-24 — — EP disclosed
US-20160031857-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2016-02-04 — — US disclosed
WO-2014170020-A1 SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2014-10-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160031857-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS TYMP, PDE4A, DPYD PDE4B 4/4885PDGFRB 1767/4885PDGFRA 1829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback